254 related articles for article (PubMed ID: 31767020)
21. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
22. Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
Zhao JJ; Kumarakulasinghe NB; Muthu V; Lee M; Walsh R; Low JL; Choo J; Tan HL; Chong WQ; Ang Y; Chan G; Yong WP; Huang Y; Ngoi N; Wong A
Oncology; 2021; 99(3):192-202. PubMed ID: 33440374
[TBL] [Abstract][Full Text] [Related]
23. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
[TBL] [Abstract][Full Text] [Related]
24. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
[TBL] [Abstract][Full Text] [Related]
25. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
26. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
27. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
28. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
Front Immunol; 2021; 12():657951. PubMed ID: 34531849
[TBL] [Abstract][Full Text] [Related]
29. A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma.
Kato T; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya YU; Wang C; Hatano K; Kawashima A; Ujike T; Kawasaki K; Morii E; Gotoh K; Eguchi H; Kiyotani K; Fujita K; Nonomura N; Uemura M
Anticancer Res; 2020 Sep; 40(9):4875-4883. PubMed ID: 32878775
[TBL] [Abstract][Full Text] [Related]
30. CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.
Chong TW; Goh FY; Sim MY; Huang HH; Thike AA; Lim WK; Teh BT; Tan PH
J Clin Pathol; 2015 Mar; 68(3):200-5. PubMed ID: 25477528
[TBL] [Abstract][Full Text] [Related]
31. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
[TBL] [Abstract][Full Text] [Related]
32. NUF2 is correlated with a poor prognosis and immune infiltration in clear cell renal cell carcinoma.
Zheng B; Wang S; Yuan X; Zhang J; Shen Z; Ge C
BMC Urol; 2023 May; 23(1):82. PubMed ID: 37138262
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
[TBL] [Abstract][Full Text] [Related]
34. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
[TBL] [Abstract][Full Text] [Related]
35. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
[TBL] [Abstract][Full Text] [Related]
36. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
37. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
[TBL] [Abstract][Full Text] [Related]
38. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
[TBL] [Abstract][Full Text] [Related]
40. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]